Mumbai, Sao Paulo, November 28, 2022: Global pharma major, Lupin Limited (Lupin) announced today that its wholly owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol™, Melleril™ and Dalmadorm™ for Central Nervous System related conditions, Bacrocin™, Glyquin™, Solaquin™, Oxipelle™ and Efurix™ as topical oncological treatments, and Cuprimine™ for the treatment of Wilson’s disease. This move reinforces our commitment to making healthcare solutions accessible to all patients.
“The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness,” said Alexandre Franca, Managing Director, MedQuímica. “This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market.”
MedQuímica Pharmaceutical Industries, with its factory located in the Industrial District of Juiz de Fora, has been operating for 47 years. In 2015 it became part of the Lupin Group, a global pharmaceutical company, and the fifth largest generics company in the United States by prescriptions and eighth largest company for generic medicine in the world. In Brazil, Medquímica develops an extensive line of both solid and liquid medicines classified into five lines: OTC (Over the counter medicines), Branded Generics, Hospital, Generics and Food Supplements.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
For further information or queries please contact –
Vice President & Global Head – Corporate CommunicationsEmail: firstname.lastname@example.org